Skip to main content

Table 1 Association between RECK expression and clinicopathological parameters

From: RECK is not an independent prognostic marker for breast cancer

Parameter

RECK negative no. cases (%)

RECK positive no. cases (%)

χ2

p-value

Age

  < 50 years

195 (18.8 %)

191 (18.4 %)

0.021

0.8848

  ≥ 50 years

324 (31.3 %)

326 (31.5 %)

Menopausal status

 Premenopausal

206 (20.1 %)

197 (19.1 %)

0.082

0.7752

 Postmenopausal

312 (30.4 %)

312 (30.4 %)

Tumor size

  < 5 cm

252 (25.5 %)

268 (27.1 %)

1.494

0.2216

  ≥ 5 cm

247 (24.9 %)

223 (22.5 %)

Lymph node stage

 Negative (N0)

169 (16.6 %)

160 (15.7 %)

0.243

0.6222

 Positive (N1, N2, N3)

341 (33.5 %)

348 (34.2 %)

Recurrence

 Negative

257 (25.1 %)

259 (25.3 %)

0.063

0.8014

 Positive

258 (25.2 %)

250 (24.4 %)

ER/PR status

 ER+/PR+

208 (22.3 %)

204 (22.0 %)

8.001

0.046

 ER+/PR-

125 (13.5 %)

86 (9.3 %)

 ER-/PR+

8 (0.9 %)

11 (1.2 %)

 ER-/PR-

135 (14.5 %)

151 (16.3 %)

Histological grade

 1

86 (8.3 %)

73 (7.1 %)

14.257

0.0008

 2

315 (30.5 %)

273 (26.4 %)

 3

116 (11.2 %)

170 (16.5 %)

TNM stage

 1

39 (3.8 %)

17 (1.6 %)

11.069

0.0114

 2A and 2B

201 (19.5 %)

204 (19.7 %)

 3A, 3B, and 3C

240 (23.2 %)

240 (23.2 %)

 4

39 (3.8 %)

54 (5.2 %)

  1. χ2, Chi-square test coefficient; ER/PR, estrogen receptor/progesterone receptor
  2. p-values considered significant after FDR correction were highlighted in bold